Literature DB >> 10428316

Clinical aspects of ovarian hyperstimulation syndrome.

J G Schenker1.   

Abstract

Ovarian hyperstimulation syndrome (OHSS) is characterized by massive transudation of protein-rich fluid (mainly albumin) from the vascular space into the peritoneal pleural and to a lesser extent to the pericardial cavities. The intensity of the syndrome is related to the degree of the follicular response in the ovaries to the ovulation inducing agents. OHSS is still a threat to every patient undergoing ovulation induction. The pathophysiology of OHSS is of extreme importance in the face of the increased use of ovulation induction agents as well as the development of sophisticated assisted reproductive techniques. The correlation found between plasma cytokine activities and the severity of OHSS suggests that plasma cytokines may be involved in the pathogenesis of OHSS and may serve as a means of monitoring the syndrome during the acute phase and throughout convalescence. The interactions between cytokine and non-cytokine mediators of the syndrome, such as the renin-angiotensin system and vascular endothelial growth factor were recently clarified. Awareness of possible mechanisms and factors in the pathophysiology of OHSS will hopefully provide opportunities to design specific treatment regimens effective for both prevention and treatment of this potentially fatal iatrogenic condition. Among IVF patients with severe and critical OHSS, pregnancy rates, multiple gestations, miscarriage, preterm premature rupture of the membranes, prematurity, and low birth weight rates are significantly higher than those reported previously for pregnancies after assisted conception. The incidence of other obstetrical complications, as well as congenital malformations and Cesarean section rates are not significantly different.

Entities:  

Mesh:

Year:  1999        PMID: 10428316     DOI: 10.1016/s0301-2115(98)00276-0

Source DB:  PubMed          Journal:  Eur J Obstet Gynecol Reprod Biol        ISSN: 0301-2115            Impact factor:   2.435


  7 in total

1.  GnRH agonist trigger for women with breast cancer undergoing fertility preservation by aromatase inhibitor/FSH stimulation.

Authors:  Kutluk Oktay; Ilgın Türkçüoğlu; Kenny A Rodriguez-Wallberg
Journal:  Reprod Biomed Online       Date:  2010-03-06       Impact factor: 3.828

2.  Thrombophilia and ovarian hyperstimulation syndrome: a case report.

Authors:  Gary Levy; Richard S Lucidi
Journal:  Hawaii Med J       Date:  2011-05

3.  Glycoprotein hormone receptors: determinants in leucine-rich repeats responsible for ligand specificity.

Authors:  Guillaume Smits; Mercedes Campillo; Cédric Govaerts; Véronique Janssens; Christine Richter; Gilbert Vassart; Leonardo Pardo; Sabine Costagliola
Journal:  EMBO J       Date:  2003-06-02       Impact factor: 11.598

4.  Effect of varying doses of tamoxifen on ovarian histopathology, serum VEGF, and endothelin 1 levels in ovarian hyperstimulation syndrome: an experimental study.

Authors:  Şehmus Pala; Remzi Atilgan; Zehra Sema Ozkan; Salih Burçin Kavak; Nevin Ilhan; Nusret Akpolat; Ekrem Sapmaz
Journal:  Drug Des Devel Ther       Date:  2015-03-24       Impact factor: 4.162

5.  Can a cyclooxygenase inhibitor be an option for treatment of ovarian hyperstimulation syndrome?

Authors:  Hasan Çilgin
Journal:  Drug Des Devel Ther       Date:  2019-04-05       Impact factor: 4.162

6.  Symptomatic isolated pleural effusion as an atypical presentation of ovarian hyperstimulation syndrome.

Authors:  Christine M Mullin; M Elizabeth Fino; Andrea Reh; Jamie A Grifo; Frederick Licciardi
Journal:  Case Rep Obstet Gynecol       Date:  2011-08-07

7.  Are pregnancy rates compromised following embryo freezing to prevent OHSS?

Authors:  Gerard J Fitzmaurice; Claire Boylan; Neil McClure
Journal:  Ulster Med J       Date:  2008-09
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.